Literature DB >> 18768962

Antiretroviral therapy prior to acute viral replication preserves CD4 T cells in the periphery but not in rectal mucosa during acute simian immunodeficiency virus infection.

Muhamuda Kader1, Wail M Hassan, Matthew Eberly, Michael Piatak, Jeffrey D Lifson, Mario Roederer, Joseph J Mattapallil.   

Abstract

The rectal mucosa is a major site for human immunodeficiency virus entry and CD4 T-cell depletion. The early and near-total loss of these cells from the rectal mucosa severely compromises the ability of the mucosal immune system to control various opportunistic infections. Protecting these cells from infection and destruction can delay disease progression, leading to a better long-term outcome. Here we show that effective suppression of viral infection in memory CD4 T cells from the rectal mucosa and peripheral blood to a very low level with antiretroviral therapy (ART) initiated prior to the peak of infection is associated with opposite outcomes in these tissues. A near-total loss of CD4 T cells in the rectal mucosa contrasted with preservation of most memory CD4 T cells in peripheral blood during the course of treatment. Interestingly, ART significantly reduced viral infection in memory CD4 T cells from both rectal mucosa and peripheral blood. Although early ART was of limited value in protecting the CD4 T cells in the rectal mucosa, the significant preservation of peripheral CD4 T cells could contribute to maintaining immune competence, leading to a better long-term outcome.

Entities:  

Mesh:

Year:  2008        PMID: 18768962      PMCID: PMC2573260          DOI: 10.1128/JVI.01143-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.

Authors:  M A Nowak; A L Lloyd; G M Vasquez; T A Wiltrout; L M Wahl; N Bischofberger; J Williams; A Kinter; A S Fauci; V M Hirsch; J D Lifson
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Development and homeostasis of T cell memory in rhesus macaque.

Authors:  Christine J Pitcher; Shoko I Hagen; Joshua M Walker; Richard Lum; Bridget L Mitchell; Vernon C Maino; Michael K Axthelm; Louis J Picker
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

4.  HIV preferentially infects HIV-specific CD4+ T cells.

Authors:  Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

5.  HIV-1 gp120 accelerates Fas-mediated activation-induced human lamina propria T cell apoptosis.

Authors:  M Boirivant; M Viora; L Giordani; A L Luzzati; A M Pronio; C Montesani; O Pugliese
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

6.  Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.

Authors:  J D Lifson; M Piatak; A N Cline; J L Rossio; J Purcell; I Pandrea; N Bischofberger; J Blanchard; R S Veazey
Journal:  J Med Primatol       Date:  2003-08       Impact factor: 0.667

7.  Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.

Authors:  Moraima Guadalupe; Elizabeth Reay; Sumathi Sankaran; Thomas Prindiville; Jason Flamm; Andrew McNeil; Satya Dandekar
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

9.  Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover.

Authors:  Kara B Anthony; Christian Yoder; Julia A Metcalf; Rebecca DerSimonian; Jan M Orenstein; Randy A Stevens; Judy Falloon; Michael A Polis; H Clifford Lane; Irini Sereti
Journal:  J Acquir Immune Defic Syndr       Date:  2003-06-01       Impact factor: 3.731

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  20 in total

1.  Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis.

Authors:  Ellen N Kersh; Wei Luo; Qi Zheng; Debra R Adams; Debra Hanson; Ae S Youngpairoj; Mian-er Cong; Katherine Butler; R Michael Hendry; Janet M McNicholl; Walid Heneine; J Gerardo Garcia-Lerma
Journal:  J Infect Dis       Date:  2012-06-27       Impact factor: 5.226

2.  Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.

Authors:  Nonhlanhla N Mkhize; Pamela P Gumbi; Lenine J Liebenberg; Yuan Ren; Peter Smith; Lynette Denny; Jo-Ann S Passmore
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques.

Authors:  Jeffy George; Egidio Brocca Cofano; Elizabeth Lybarger; Mark Louder; Bernard A P Lafont; John R Mascola; Marjorie Robert-Guroff; Joseph J Mattapallil
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-17       Impact factor: 2.205

4.  Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo.

Authors:  Justin M Greene; Jennifer J Lhost; Benjamin J Burwitz; Melisa L Budde; Caitlin E Macnair; Madelyn K Weiker; Emma Gostick; Thomas C Friedrich; Karl W Broman; David A Price; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

5.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

6.  Suppressed Th17 levels correlate with elevated PIAS3, SHP2, and SOCS3 expression in CD4 T cells during acute simian immunodeficiency virus infection.

Authors:  Sandra L Bixler; Netanya G Sandler; Daniel C Douek; Joseph J Mattapallil
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

7.  A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.

Authors:  Jason B Dinoso; S Alireza Rabi; Joel N Blankson; Lucio Gama; Joseph L Mankowski; Robert F Siliciano; M Christine Zink; Janice E Clements
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

8.  CD4 T cell subsets in the mucosa are CD28+Ki-67-HLA-DR-CD69+ but show differential infection based on alpha4beta7 receptor expression during acute SIV infection.

Authors:  M Kader; S Bixler; M Roederer; R Veazey; J J Mattapallil
Journal:  J Med Primatol       Date:  2009-10       Impact factor: 0.667

Review 9.  Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies.

Authors:  Gregory Q Del Prete; Jeffrey D Lifson
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

Review 10.  Using nonhuman primates to model HIV transmission.

Authors:  Christine M Fennessey; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.